IRIS Accounts Production v24.2.0.383 14319637 Board of Directors 1.9.23 31.8.24 31.8.24 false true false false false true false Ordinary 0.01000 0.01000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh143196372023-08-31143196372024-08-31143196372023-09-012024-08-31143196372022-08-25143196372022-08-262023-08-31143196372023-08-3114319637ns15:EnglandWales2023-09-012024-08-3114319637ns14:PoundSterling2023-09-012024-08-3114319637ns10:Director12023-09-012024-08-3114319637ns10:PrivateLimitedCompanyLtd2023-09-012024-08-3114319637ns10:SmallEntities2023-09-012024-08-3114319637ns10:AuditExempt-NoAccountantsReport2023-09-012024-08-3114319637ns10:SmallCompaniesRegimeForDirectorsReport2023-09-012024-08-3114319637ns10:SmallCompaniesRegimeForAccounts2023-09-012024-08-3114319637ns10:FullAccounts2023-09-012024-08-311431963712023-09-012024-08-3114319637ns10:OrdinaryShareClass12023-09-012024-08-311431963711ns10:OrdinaryShareClass12023-09-012024-08-3114319637ns10:Director22023-09-012024-08-3114319637ns10:RegisteredOffice2023-09-012024-08-3114319637ns5:CurrentFinancialInstruments2024-08-3114319637ns5:CurrentFinancialInstruments2023-08-3114319637ns5:ShareCapital2024-08-3114319637ns5:ShareCapital2023-08-3114319637ns5:SharePremium2024-08-3114319637ns5:SharePremium2023-08-3114319637ns5:RetainedEarningsAccumulatedLosses2024-08-3114319637ns5:RetainedEarningsAccumulatedLosses2023-08-3114319637ns5:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3114319637ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-09-012024-08-3114319637ns5:PlantMachinery2023-09-012024-08-3114319637ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-08-3114319637ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-08-3114319637ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-08-3114319637ns5:PlantMachinery2024-08-3114319637ns5:WithinOneYearns5:CurrentFinancialInstruments2024-08-3114319637ns5:WithinOneYearns5:CurrentFinancialInstruments2023-08-3114319637ns10:OrdinaryShareClass12024-08-31
REGISTERED NUMBER: 14319637 (England and Wales)











Mipro Medical Solutions Ltd

Unaudited Financial Statements

for the Year Ended 31 August 2024






Mipro Medical Solutions Ltd (Registered number: 14319637)






Contents of the Financial Statements
for the Year Ended 31 August 2024




Page

Company information 1

Balance sheet 2

Notes to the financial statements 4


Mipro Medical Solutions Ltd

Company Information
for the Year Ended 31 August 2024







Directors: Dr D M Glover
Dr S Whatmough





Registered office: 28 Huncoat Avenue
Stockport
SK4 5HN





Registered number: 14319637 (England and Wales)





Accountants: Warr & Co Limited
Chartered Accountants
Mynshull House
78 Churchgate
Stockport
Cheshire
SK1 1YJ

Mipro Medical Solutions Ltd (Registered number: 14319637)

Balance Sheet
31 August 2024

31.8.24 31.8.23
Notes £    £   
Fixed assets
Intangible assets 4 1,266,142 377,444
Tangible assets 5 691 -
1,266,833 377,444

Current assets
Debtors 6 176,062 37,687
Cash at bank and in hand 466,344 200,521
642,406 238,208
Creditors
Amounts falling due within one year 7 (1,225 ) (192,235 )
Net current assets 641,181 45,973
Total assets less current liabilities 1,908,014 423,417

Capital and reserves
Called up share capital 8 13,455 11,351
Share premium 1,920,559 430,813
Retained earnings (26,000 ) (18,747 )
Shareholders' funds 1,908,014 423,417

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 August 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 August 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Mipro Medical Solutions Ltd (Registered number: 14319637)

Balance Sheet - continued
31 August 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 26 September 2024 and were signed on its behalf by:





Dr S Whatmough - Director


Mipro Medical Solutions Ltd (Registered number: 14319637)

Notes to the Financial Statements
for the Year Ended 31 August 2024

1. Statutory information

Mipro Medical Solutions Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. Accounting policies

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements have been prepared on a going concern basis on the grounds that the directors will continue to provide sufficient finance to enable the company to continue trading for the foreseeable future.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Development costs are being amortised evenly over their estimated useful life of six years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on cost

3. Employees and directors

The average number of employees during the year was 2 (2023 - 2 ) .

Mipro Medical Solutions Ltd (Registered number: 14319637)

Notes to the Financial Statements - continued
for the Year Ended 31 August 2024

4. Intangible fixed assets
Development
costs
£   
Cost
At 1 September 2023 377,444
Additions 951,605
At 31 August 2024 1,329,049
Amortisation
Amortisation for year 62,907
At 31 August 2024 62,907
Net book value
At 31 August 2024 1,266,142
At 31 August 2023 377,444

5. Tangible fixed assets
Plant and
machinery
etc
£   
Cost
Additions 922
At 31 August 2024 922
Depreciation
Charge for year 231
At 31 August 2024 231
Net book value
At 31 August 2024 691

Mipro Medical Solutions Ltd (Registered number: 14319637)

Notes to the Financial Statements - continued
for the Year Ended 31 August 2024

6. Debtors: amounts falling due within one year
31.8.24 31.8.23
£    £   
Trade debtors 6,000 -
Other debtors 118,999 2,000
VAT 51,063 35,687
176,062 37,687

7. Creditors: amounts falling due within one year
31.8.24 31.8.23
£    £   
Other creditors 1,225 192,235

8. Called up share capital

Allotted, issued and fully paid:
Number: Class: Nominal 31.8.24 31.8.23
value: £    £   
1,345,484 Ordinary £0.01 13,455 11,351

350,434 Ordinary shares of £0.01 each were allotted as fully paid at a premium of 4.25 per share during the year.